You are here


Mobile Interconnected Evaluation and Learning Software

Primary tabs

The National Institute on Drug Abuse (NIDA) seeks licensing and/or co-development research collaborations for use of software for substance use disorders, behavior modification, and cancer patient care and pain management, etc. NIDA has developed software that permits real-time communication of patient-reported data and associated geolocation data. The software can be used in patient treatment or as a research tool for evaluating effectiveness of treatments.
NIH Reference Number
Product Type
  • Mobile Health Monitoring; mHealth, Real-time Data Exchange; Clinical Research Informatics; Ecological Momentary Assessment; Electronic Health Record; EHR, Substance Use Disorders, Behavioral Modification, Telemedicine, National Institute on Drug Abuse
  • NIDA, Vahabzadeh
Collaboration Opportunity
This invention is available for licensing and co-development.
Description of Technology

The National Institute on Drug Abuse (NIDA), Biomedical Informatics section, developed the Mobile Interconnected Evaluation & Learning (MIEL) as a mobile health application. MIEL is used for real-time communication of patient-reported assessment data associated with automatically collected geolocation data on one side and the user’s enterprise-scale patient record system on the other. The reported data are for treating polydrug substance abuse or other modalities, as well as the associated risky behaviors, and are interconnected to the patient’s electronic health record system managed at the research facilities. This invention addresses the need for real-time integration of the collected data with information already existing in the patients’ clinical research database to apply intelligent decision support systems for delivery of best care and treatment. MIEL addresses this requirement by allowing early reporting of various data related to drug dependence, including but not limited to substance abuse or craving data in addition to psychosocial state of the patients to the researchers and physicians. This enables the provision of information for better designs in future patient-centric research, ultimately helping to improve treatment outcomes adaptable to the changing needs of individuals relevant to exposed risks. 

Potential Commercial Applications
  • MIEL can potentially help patients connect with their inner awareness from the start, knowing when and what to ask for help. It also helps them connect to the loved ones and health care network as they progress in their journey to recovery
  • MIEL can easily serve as an adverse event reporting tool. It simply treats it as a questionnaire with choices of answers for intensity and frequencies
  • It can be used as a Software as a Service (SaaS) or the entire code can be licensed
  • It can be modified to use in other fields such as: alcoholism, HIV/AIDS, cancer, behavior modification, pain management, and compliance related processes
Competitive Advantages
  • Provides smart, secure bidirectional interconnection between enterprise systems and smartphones 
  • Checks for the availability of wireless network and if there is no coverage, to prevent data loss, stores patient data locally; when coverage becomes available again, it resumes data transfer without any data loss 
  • One assessment’s responses can trigger another assessment
  • Automatically initiates timed follow-up questionnaires contingent upon reported events (e.g., a drink of alcohol, craving for and use of cocaine and heroin, etc.) in real-time
  • Integrates on-board GPS with the capability, algorithm, and logic for mobile intervention delivery based on geolocation risks
  • Software runs on Android devices

Massoud R Vahabzadeh Ph.D. (NIDA), Mustapha Mezghanni M.S. (NIDA), Jia-Ling Lin Ph.D. (NIDA)

Development Stage
Patent Status
  • Research Material: NIH will not pursue patent prosecution for this technology
Related Technologies
Friday, February 16, 2018